top of page

Ignition of the next stage - Lunaphore closes CHF 23m Series C


Redalpine is proud to continue their support of the Lunaphore team in their latest fundraising round


Our portfolio company Lunaphore Technologies (Redalpine Capital II), a Lausanne-based company developing innovative next-generation solutions for cancer research and tissue diagnostics, today proudly announced the closing of its CHF 23m Series C round. The financing was led by the Japanese investor PHC Holdings Corporation (formerly Panasonic Health), a global healthcare company that owns Epredia, a leading provider of comprehensive solutions for precision cancer diagnostics. Existing investors including Redalpine also participated in this financing round.


The proceeds will further fund the product pipeline and market expansion. Specifically, Lunaphore is now preparing its US market entry and ramping up activities in Europe. PHC Holdings Corporation with its global distribution network present in more than 125 countries as well as Epredia’s specialist knowledge in the field of anatomical pathology will both significantly support Lunaphore in scaling and speeding up this expansion process.


“We are thrilled by the confidence placed in Lunaphore by our existing investors as well as the new ones in this financing round. The interest of global players in healthcare, like PHC Holdings Corporation demonstrates the relevance and added value of Lunaphore’s technology and confirms its high potential to transform the field of tissue analytics” said Ata Tuna Ciftlik, Lunaphore’s CEO.


Redalpine congratulates the entire Lunaphore team on this major milestone and looks forward to the next steps together.


For further information, please check out Lunaphore's press release or visit the websites of Lunaphore, PHC Holding Corporation, and Epredia.  

Comments


bottom of page